OnKure Therapeutics
OKUR
41 hedge funds and large institutions have $50.8M invested in OnKure Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
5% more funds holding
Funds holding: 39 → 41 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.61% less ownership
Funds ownership: 71.31% → 70.7% (-0.61%)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
66% less capital invested
Capital invested by funds: $149M → $50.8M (-$98.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$125K |
| 2 |
JG
Jefferies Group
New York
|
+$119K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$59.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$47.9K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$44.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tybourne Capital Management
Hong Kong
|
-$280K |
| 2 |
PCM
Pinz Capital Management
New York
|
-$242K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$232K |
| 4 |
Millennium Management
New York
|
-$214K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$170K |
OKUR Hedge Fund Activity: Q1 2022 in Review
41 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2022, worth a combined $50.8M — down 66% from $149M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OKUR positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 13 trimmed.
The largest buyer was Commonwealth Equity Services, opening a new position worth an estimated $125K. The largest seller was Tybourne Capital Management, cutting an estimated $280K.
- 41 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2022, up from 39 in Q4 2021.
- Funds reported $50.8M of OnKure Therapeutics stock for Q1 2022, down 66% quarter-over-quarter.
- 5 funds opened new OnKure Therapeutics positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest OnKure Therapeutics buyer in Q1 2022 was Commonwealth Equity Services, an estimated $125K added.
- The largest OnKure Therapeutics seller in Q1 2022 was Tybourne Capital Management, an estimated $280K sold.
Based on aggregated 13F filings for Q1 2022.